<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00993148</url>
  </required_header>
  <id_info>
    <org_study_id>MIDAS</org_study_id>
    <nct_id>NCT00993148</nct_id>
  </id_info>
  <brief_title>Maraviroc Plus Darunavir/Ritonavir for Treatment-Naïve Patients Infected With R5-tropic HIV-1</brief_title>
  <acronym>MIDAS</acronym>
  <official_title>Maraviroc Plus Darunavir/Ritonavir Study for Treatment-Naïve Patients Infected With R5-tropic HIV-1 Based on Enhanced Sensitivity Trofile</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tibotec, Inc</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety and efficacy of a novel combination
      antiretroviral therapy regimen consisting of maraviroc plus darunavir/ritonavir in
      treatment-naive patients infected with R5-tropic HIV-1. The hypothesis is that in
      treatment-naive subjects infected with R5-tropic HIV-1, combination antiretroviral therapy
      with maraviroc plus darunavir/ritonavir is well tolerated and efficacious.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">April 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &gt;50</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of participants with confirmed plasma HIV-1 RNA &gt; 50 copies/mL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Virologic Failure or Off Study Treatment Regimen</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of participants with virologic failure (confirmed plasma HIV-1 RNA &gt; 50 copies/mL) or off study treatment regimen (composite end point)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher</measure>
    <time_frame>96 weeks</time_frame>
    <description>Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES</measure>
    <time_frame>At study entry and at the time of virologic failure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Drug Adherence, Number of Participants With Missed Doses</measure>
    <time_frame>Week 24</time_frame>
    <description>Drug adherence, assessed as number of participants with missed doses over four-day recall</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Concentrations (Ctrough) of Maraviroc</measure>
    <time_frame>24 hours</time_frame>
    <description>Average trough concentration (Ctrough) of maraviroc</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median CD4 Count Change From Baseline</measure>
    <time_frame>96 weeks</time_frame>
    <description>Median changes from baseline in peripheral CD4+ T-cell count</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</measure>
    <time_frame>96 weeks</time_frame>
    <description>Proportion of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>HIV-1 Infection</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Maraviroc plus darunavir/ritonavir</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm open label trial of maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily for 96 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>maraviroc</intervention_name>
    <description>150 mg tab by mouth once daily for 96 weeks</description>
    <arm_group_label>Maraviroc plus darunavir/ritonavir</arm_group_label>
    <other_name>Selzentry</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>darunavir</intervention_name>
    <description>800 mg tab by mouth once daily for 96 weeks</description>
    <arm_group_label>Maraviroc plus darunavir/ritonavir</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ritonavir</intervention_name>
    <description>100 mg capsule by mouth once daily for 96 weeks</description>
    <arm_group_label>Maraviroc plus darunavir/ritonavir</arm_group_label>
    <other_name>norvir</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection, as documented by any licensed HIV test kit and confirmed by Western
             blot, HIV-1 culture, HIV-1 antigen, plasma HIV-1 RNA, or a second antibody test by a
             method other than ELISA any time prior to study entry

          -  Plasma HIV-1 RNA 5, 000 to 500,000 copies/mL obtained within 90 days prior to study
             entry

          -  Exclusive R5 tropism based on enhanced sensitivity Trofile assay done within 90 days
             prior to entry

          -  CD4 cell count &gt; 100 cells/mm3 within 90 days prior to study entry

          -  HIV genotype (for RT and protease) performed at any time before study entry (Subjects
             with single or combination NNRTI or NRTI RAM(s) at screening are permitted)

          -  ARV drug-naïve, defined as no previous ARV treatment at any time prior to study entry

          -  Negative result from a hepatitis B surface antigen test performed within 90 days prior
             to study entry

          -  Negative result from a hepatitis C antibody test performed within 90 days prior to
             study entry

          -  Laboratory values obtained within 30 days prior to study entry:

               -  ANC &gt;=750/mm3

               -  Hemoglobin &gt;=10 g/dL

               -  Platelets &gt;=50,000/mm3

               -  AST (SGOT), ALT (SGPT), and alkaline phosphatase &lt;=5 x ULN

               -  Calculated creatinine clearance (CrCl) &gt;=30 mL/min, as estimated by the
                  Cockcroft-Gault equation*

          -  Negative serum or urine pregnancy test within 48 hours prior to study entry for women
             with reproductive potential

          -  If participating in sexual activity that could lead to pregnancy, the study subjects
             with reproductive potential must use one form of contraceptive while receiving
             protocol-specified medications and for 60 days after stopping the medications.

          -  Men and women age &gt;=18 years

          -  Ability and willingness of subject or legal guardian/representative to provide
             informed consent

        Exclusion Criteria:

          -  Serious illness requiring systemic treatment and/or hospitalization until candidate
             either completes therapy or is clinically stable on therapy, in the opinion of the
             site investigator, for at least 7 days prior to study entry

          -  Screening HIV genotype obtained any time prior to study entry with any DRV RAM (V11I,
             V32I, L33F, I47V, I50V, I54L, I54M, T74P, L76V, I84V, and L89V)

          -  Treatment within 30 days prior to study entry with immune modulators such as systemic
             steroids, interleukins, interferons, granulocyte colony-stimulating factor (G-CSF),
             erythropoietin, or any investigational therapy. NOTE: Subjects receiving stable
             physiologic glucocorticoid doses (defined as prednisone ≤10 mg/day [or equivalent] as
             a stable or tapering dose) are permitted. Subjects receiving corticosteroids for acute
             therapy for PCP or asthma exacerbation, or receiving a short course (defined as ≤2
             weeks of pharmacologic glucocorticoid therapy) are permitted

          -  Breast-feeding

          -  Requirement for any medication that is prohibited with a study medication

          -  Known allergy/sensitivity to study drugs or their formulations. A history of sulfa
             allergy is not an exclusion

          -  Active drug or alcohol use or dependence that could interfere with adherence to study
             requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Babafemi Taiwo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CORECenter</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Nebraska</name>
      <address>
        <city>Omaha</city>
        <state>Nebraska</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Taiwo B, Acosta EP, Ryscavage P, Berzins B, Lu D, Lalezari J, Castro J, Adeyemi O, Kuritzkes DR, Eron JJ, Tsibris A, Swindells S. Virologic response, early HIV-1 decay, and maraviroc pharmacokinetics with the nucleos(t)ide-free regimen of maraviroc plus darunavir/ritonavir in a pilot study. J Acquir Immune Defic Syndr. 2013 Oct 1;64(2):167-73. doi: 10.1097/QAI.0b013e3182a03d95.</citation>
    <PMID>23797691</PMID>
  </results_reference>
  <verification_date>August 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 8, 2009</study_first_submitted>
  <study_first_submitted_qc>October 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 12, 2009</study_first_posted>
  <results_first_submitted>July 28, 2014</results_first_submitted>
  <results_first_submitted_qc>July 28, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 19, 2014</results_first_posted>
  <last_update_submitted>August 26, 2014</last_update_submitted>
  <last_update_submitted_qc>August 26, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 5, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Babafemi Taiwo</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment naive</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Maraviroc</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Maraviroc + Darunavir/Ritonavir</title>
          <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>never initiated treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>HIV-infected treatment naïve participants with R5 virus</population>
      <group_list>
        <group group_id="B1">
          <title>Maraviroc + Darunavir/Ritonavir</title>
          <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38" lower_limit="31" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>More than one race</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown or Not Reported</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Median HIV-1 RNA</title>
          <description>Median HIV-1 RNA</description>
          <units>log 10 copies</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.62" lower_limit="4.18" upper_limit="4.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &gt;50</title>
        <description>Percentage of participants with confirmed plasma HIV-1 RNA &gt; 50 copies/mL</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &gt;50</title>
          <description>Percentage of participants with confirmed plasma HIV-1 RNA &gt; 50 copies/mL</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Virologic Failure or Off Study Treatment Regimen</title>
        <description>Percentage of participants with virologic failure (confirmed plasma HIV-1 RNA &gt; 50 copies/mL) or off study treatment regimen (composite end point)</description>
        <time_frame>24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Virologic Failure or Off Study Treatment Regimen</title>
          <description>Percentage of participants with virologic failure (confirmed plasma HIV-1 RNA &gt; 50 copies/mL) or off study treatment regimen (composite end point)</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.5" lower_limit="2.7" upper_limit="32.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</title>
        <description>Percentage of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
        <time_frame>48 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</title>
          <description>Percentage of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" lower_limit="1.0" upper_limit="27.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher</title>
        <description>Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Signs/Symptoms or Laboratory Toxicities of Grade 3 or Higher</title>
          <description>Signs/symptoms or laboratory toxicities of Grade 3 or higher, or of any grade which led to a permanent change or discontinuation of study treatment regimen</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES</title>
        <time_frame>At study entry and at the time of virologic failure</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Resistance Mutations and Co-receptor Tropism Assessed by Trofile ES</title>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Drug Adherence, Number of Participants With Missed Doses</title>
        <description>Drug adherence, assessed as number of participants with missed doses over four-day recall</description>
        <time_frame>Week 24</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Drug Adherence, Number of Participants With Missed Doses</title>
          <description>Drug adherence, assessed as number of participants with missed doses over four-day recall</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Concentrations (Ctrough) of Maraviroc</title>
        <description>Average trough concentration (Ctrough) of maraviroc</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Concentrations (Ctrough) of Maraviroc</title>
          <description>Average trough concentration (Ctrough) of maraviroc</description>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.3" spread="22.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median CD4 Count Change From Baseline</title>
        <description>Median changes from baseline in peripheral CD4+ T-cell count</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Median CD4 Count Change From Baseline</title>
          <description>Median changes from baseline in peripheral CD4+ T-cell count</description>
          <units>cells per mm^3</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247" lower_limit="119" upper_limit="340"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Proportion of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</title>
        <description>Proportion of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
        <time_frame>96 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Maraviroc + Darunavir/Ritonavir</title>
            <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
          </group>
        </group_list>
        <measure>
          <title>Proportion of Participants With Plasma HIV-1 RNA &gt;50 Copies/mL</title>
          <description>Proportion of participants with confirmed plasma HIV-1 RNA level &gt;50 copies/mL</description>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10" lower_limit="1.2" upper_limit="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Maraviroc + Darunavir/Ritonavir</title>
          <description>maraviroc 150 mg plus darunavir/ritonavir 800/100 mg once daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Babafemi Taiwo</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-695-5085</phone>
      <email>b-taiwo@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

